Long-term administration of escitalopram in patients with social anxiety disorder in Japan
Satoshi Asakura,1 Taiji Hayano,2 Atsushi Hagino,2 Tsukasa Koyama3 1Health Care Center and Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, 2Clinical Development Planning and Management, Mochida Pharmaceutical Co., Ltd, Tokyo, 3Clinical Research Center, O...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-07-01
|
| Series: | Neuropsychiatric Disease and Treatment |
| Subjects: | |
| Online Access: | https://www.dovepress.com/long-term-administration-of-escitalopram-in-patients-with-social-anxie-peer-reviewed-fulltext-article-NDT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839651698893651968 |
|---|---|
| author | Asakura S Hayano T Hagino A Koyama T Sasai S |
| author_facet | Asakura S Hayano T Hagino A Koyama T Sasai S |
| author_sort | Asakura S |
| collection | DOAJ |
| description | Satoshi Asakura,1 Taiji Hayano,2 Atsushi Hagino,2 Tsukasa Koyama3 1Health Care Center and Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, 2Clinical Development Planning and Management, Mochida Pharmaceutical Co., Ltd, Tokyo, 3Clinical Research Center, Oyachi Hospital, Sapporo, Hokkaido, Japan Purpose: To investigate the safety, tolerability, and effectiveness of escitalopram in patients with social anxiety disorder in Japan.Methods: A 52-week, open-label study was conducted in Japanese patients with social anxiety disorder with a total score ≥60 on the Liebowitz Social Anxiety Scale – Japanese Version (LSAS-J) and ≥4 on the Clinical Global Impression – Severity Scale. Escitalopram 10 mg/day was administered for the first week and could be increased to 20 mg/day.Results: The study included 158 patients: 81.0% (128/158) completed 52 weeks of escitalopram treatment, 68.4% (108/158) increased their dose to 20 mg/day, and 56.3% (89/158) remained on 20 mg/day. Adverse drug reactions were reported by 57.6% (91/158) of patients. The most common (incidence ≥10%) were somnolence and nausea. The incidence of adverse drug reactions was similar in extensive and poor metabolizers of cytochrome P450 2C19. No adverse drug reactions increased in incidence by >5% after week 12. The incidence of serious adverse events was 1.3% (2/158). No deaths occurred. The LSAS-J total scores improved until week 52. The LSAS-J response rate (≥30% improvement in LSAS-J) was 69.0%, the Clinical Global Impression – Improvement Scale response rate (≤2) was 73.0%, and the LSAS-J remission rate (≤30) was 27.0%.Conclusion: In this first 52-week clinical study of social anxiety disorder, escitalopram 10–20 mg/day was safe, well tolerated, and effective in Japanese patients. Keywords: escitalopram, Japanese, long-term study, social anxiety disorder, selective serotonin reuptake inhibitors |
| format | Article |
| id | doaj-art-72746ffc412a464cbb6f5a90c13c4f0d |
| institution | Matheson Library |
| issn | 1178-2021 |
| language | English |
| publishDate | 2016-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Neuropsychiatric Disease and Treatment |
| spelling | doaj-art-72746ffc412a464cbb6f5a90c13c4f0d2025-06-26T01:58:36ZengDove Medical PressNeuropsychiatric Disease and Treatment1178-20212016-07-01Volume 12Issue 11817182528037Long-term administration of escitalopram in patients with social anxiety disorder in JapanAsakura S0Hayano THagino A1Koyama TSasai SHealth Care Center and Department of PsychiatryClinical Development Planning and ManagementSatoshi Asakura,1 Taiji Hayano,2 Atsushi Hagino,2 Tsukasa Koyama3 1Health Care Center and Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, 2Clinical Development Planning and Management, Mochida Pharmaceutical Co., Ltd, Tokyo, 3Clinical Research Center, Oyachi Hospital, Sapporo, Hokkaido, Japan Purpose: To investigate the safety, tolerability, and effectiveness of escitalopram in patients with social anxiety disorder in Japan.Methods: A 52-week, open-label study was conducted in Japanese patients with social anxiety disorder with a total score ≥60 on the Liebowitz Social Anxiety Scale – Japanese Version (LSAS-J) and ≥4 on the Clinical Global Impression – Severity Scale. Escitalopram 10 mg/day was administered for the first week and could be increased to 20 mg/day.Results: The study included 158 patients: 81.0% (128/158) completed 52 weeks of escitalopram treatment, 68.4% (108/158) increased their dose to 20 mg/day, and 56.3% (89/158) remained on 20 mg/day. Adverse drug reactions were reported by 57.6% (91/158) of patients. The most common (incidence ≥10%) were somnolence and nausea. The incidence of adverse drug reactions was similar in extensive and poor metabolizers of cytochrome P450 2C19. No adverse drug reactions increased in incidence by >5% after week 12. The incidence of serious adverse events was 1.3% (2/158). No deaths occurred. The LSAS-J total scores improved until week 52. The LSAS-J response rate (≥30% improvement in LSAS-J) was 69.0%, the Clinical Global Impression – Improvement Scale response rate (≤2) was 73.0%, and the LSAS-J remission rate (≤30) was 27.0%.Conclusion: In this first 52-week clinical study of social anxiety disorder, escitalopram 10–20 mg/day was safe, well tolerated, and effective in Japanese patients. Keywords: escitalopram, Japanese, long-term study, social anxiety disorder, selective serotonin reuptake inhibitorshttps://www.dovepress.com/long-term-administration-of-escitalopram-in-patients-with-social-anxie-peer-reviewed-fulltext-article-NDTescitalopramJapaneselong-term studysocial anxiety disorderselective serotonin reuptake inhibitors |
| spellingShingle | Asakura S Hayano T Hagino A Koyama T Sasai S Long-term administration of escitalopram in patients with social anxiety disorder in Japan Neuropsychiatric Disease and Treatment escitalopram Japanese long-term study social anxiety disorder selective serotonin reuptake inhibitors |
| title | Long-term administration of escitalopram in patients with social anxiety disorder in Japan |
| title_full | Long-term administration of escitalopram in patients with social anxiety disorder in Japan |
| title_fullStr | Long-term administration of escitalopram in patients with social anxiety disorder in Japan |
| title_full_unstemmed | Long-term administration of escitalopram in patients with social anxiety disorder in Japan |
| title_short | Long-term administration of escitalopram in patients with social anxiety disorder in Japan |
| title_sort | long term administration of escitalopram in patients with social anxiety disorder in japan |
| topic | escitalopram Japanese long-term study social anxiety disorder selective serotonin reuptake inhibitors |
| url | https://www.dovepress.com/long-term-administration-of-escitalopram-in-patients-with-social-anxie-peer-reviewed-fulltext-article-NDT |
| work_keys_str_mv | AT asakuras longtermadministrationofescitalopraminpatientswithsocialanxietydisorderinjapan AT hayanot longtermadministrationofescitalopraminpatientswithsocialanxietydisorderinjapan AT haginoa longtermadministrationofescitalopraminpatientswithsocialanxietydisorderinjapan AT koyamat longtermadministrationofescitalopraminpatientswithsocialanxietydisorderinjapan AT sasais longtermadministrationofescitalopraminpatientswithsocialanxietydisorderinjapan |